IMR Press / CEOG / Special Issues / 1639556799283

Surgical and Therapeutic Management of Gynecological Cancer

Submission deadline: 31 August 2022
Special Issue Editors
  • Chia-Hao Liu, MD
    Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan,Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
    Interests: Ovarian cancer; Endometrial cancer; Cervical cancer; Laparoscopic surgery; Hysteroscopy; Endometriosis; Uterine myoma; Translational medicine
  • Peng-Hui Wang, MD, PhD
    Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan,Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
    Interests: Gynecological cancer surgery and treatment; Treatment of benign gynecological diseases; Women's functional diseases; Irregular menstruation; Polycystic ovary syndrome; Acne; Urinary incontinence
Special Issue Information

Dear Colleagues,

Gynecological cancers, including primary peritoneal cancer, tubo-ovarian cancer, uterine cancer, cervical cancer, vaginal cancer and vulvar cancer, remain a significant global health problem. Recent developments in surgery have contributed to the advancement of various surgical disciplines in the modern era, especially for gynecological cancers. One of these modern techniques is minimally invasive surgery, which reduces surgical intervention-related invasiveness but at the same time does not compromise therapeutic outcomes. Although surgery can be a primary treatment for most early-stage gynecological cancers, surgery might not be suitable for some patients. Moreover, patients with very advanced or recurrent disease often need multi-modality treatment or systemic therapy, as evidenced by the worse outcome of women treated by single modality therapy only. Fortunately, there is now considerable evidence showing significant therapeutic benefits from various kinds of adjuvant treatment, such as hormonal therapy, chemotherapy, targeted therapy, immunotherapy, and others. With these treatments, some patients may experience prolonged progression-free and overall survival.
This special issue welcomes investigators and clinical physicians worldwide to contribute original research articles and review articles that advance our knowledge of the management of gynecological cancers, based upon recent developments and the most updated techniques in this field.

Chia-Hao Liu and Peng-Hui Wang

Guest Editors

Keywords
Gynecological cancer
Surgical management
Minimal-invasive surgery
Adjuvant therapy
Targeted therapy
Immunotherapy
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (2 Papers)
Back to top